Reduced-dose carboplatin doublet plus cemiplimab versus cemiplimab alone for older, frail metastatic NSCLC with PD-L1 under 50%

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, open-label phase II trial comparing reduced-dose platinum-doublet chemotherapy combined with cemiplimab to cemiplimab monotherapy in patients aged 70 or older with stage III/IV NSCLC and PD-L1 <50%. Participants are screened with the G8 geriatric tool and must have ECOG 0–2 and be considered unsuitable for full-dose chemotherapy or have a G8 score ≤14. The study will collect data on efficacy, safety, and overall treatment utility to determine whether the reduced-dose combination is better tolerated and more effective than immunotherapy alone in this frail population. Treatments include cemiplimab with a reduced-dose carboplatin-based doublet (pemetrexed, paclitaxel, or gemcitabine) versus cemiplimab alone across Swiss participating centers.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Informed Consent as documented by signature
* Histologically or cytologically confirmed NSCLC. Mixed histology with small-cell component is not allowed.
* Metastatic or advanced or recurrent NSCLC without a curative-intent treatment option (surgery or chemo-radiotherapy).
* PD-L1 \<50% by local testing (SP 142 excluded)
* ≥70 years
* ECOG 0-2
* G8 screening score of ≤14 and/or ineligible for full-dose chemotherapy, defined as doses of carboplatin AUC 5, pemetrexed 500 mg/m2, paclitaxel 175 mg/m2, gemcitabine 1200 mg/m2 (as per Investigator)
* Life expectancy ≥6 months
* Patients with a prior malignancy (except NSCLC, see EC 7.2.2 and 7.2.3) and treated with curative intent are eligible if all treatment of that malignancy was completed at least 2 years before registration and the patient has no evidence of disease at registration. Less than 2 years is acceptable for malignancies with low risk of recurrence and/or no late recurrence, after consultation with CI.
* Patients with asymptomatic untreated or symptomatic treated CNS metastases are eligible if corticosteroid dose \<10 mg prednisolone equivalent/day for at least 7 days
* Patients must be suitable to receive reduced-dose carboplatin-doublet chemotherapy in combination with immunotherapy including adequate bone marrow, renal and hepatic function as follows:

  * Hemoglobin ≥90 g/L, neutrophils ≥1.5 G/L, Thrombocytes ≥100G/L
  * Creatinine clearance (Cockroft-Gault) ≥30 mL/min
  * ASAT/ALAT ≤2xULN, Bilirubin ≤1.5xULN (≤3xULN for patients with Gilbert's disease),
* Men agree not to donate sperm or father a child during trial treatment and until 6 months after the last dose of trial treatment

Exclusion Criteria:

* Actionable genomic alteration for 1L treatment (EGFR, ALK, ROS1, RET, NTRK, MET Exon14 skipping). Testing is required for any NSQ-NSCLC or patients with SCC and a smoking history of ≤10py.
* Prior systemic treatment for metastatic NSCLC.
* Prior chemotherapy and/or immunotherapy in curative-intent treatment for locally advanced NSCLC in the past 6 months.
* Oligometastatic treatment concept with induction systemic therapy and planned LAT to all lesions.
* High tumor burden with a risk of rapid critical progression, as judged by the Investigator. Careful patient selection is important in order to prevent that patients in the comparator arm are not eligible for receiving add-on reduced-dose chemotherapy anymore if primary progression occurs (e.g., pericardial infiltration, high liver metastasis load etc).
* Active, treatment-requiring auto-immune disease in the past 2 years other than vitiligo, alopecia, hypothyroidism, type 1 diabetes or diet-controlled celiac disease.
* History of pneumonitis in the past 5 years.
* Systemic corticosteroid treatment ≥10 mg/day of prednisolone-equivalent or any other systemic immunosuppressive medication within 7 days prior to first dose of study intervention (except as needed for chemotherapy premedication or for physiologic corticosteroid replacement)
* Any infection requiring hospitalization or treatment with IV anti-infectives within 2 weeks of first dose of study medication
* Uncontrolled infection with HIV, hepatitis B or hepatitis C infection
* Receipt of a live vaccine within 4 weeks of start of study medication
* Receipt of COVID-19 vaccination within 1 week of planned start of study medication or for which the planned COVID-19 vaccinations would not be completed 1 week prior to start of study medication
* Organ transplant

Where it's running

• HFR Fribourg
  Fribourg, Villars-sur-Glâne, Switzerland Recruiting
• Kantonsspital Aarau
  Aarau, Switzerland Recruiting
• Kantonsspital Baden
  Baden, Switzerland Recruiting
• Universitätsspital Basel
  Basel, Switzerland Recruiting
• EOC Istituto Oncologico della Svizzera Italiana (IOSI)
  Bellinzona, Switzerland Recruiting
• Inselspital
  Bern, Switzerland Recruiting

Study contacts

• Study coordinator: Gisela Müller
• Email: trials@swisscancerinstitute.ch
• Phone: +41 31 389 91 91

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cemiplimab with Quad Shot Radiation for Head and Neck Cutaneous Squamous Cell Carcinoma

  This study tests whether giving cemiplimab together with a short course of Quad Shot radiation can be safely delivered in several rounds to elderly or frail patients with head and neck skin cancer.

  Recruiting Early Phase 1 Vanderbilt-Ingram Cancer Center · St Louis, Missouri · NCT07869823

• First-line treatment with pembrolizumab, pemetrexed, and platinum with or without zoldonrasib for metastatic non-squamous NSCLC

  This trial tests whether adding zoldonrasib to standard pembrolizumab and platinum chemotherapy helps people with untreated metastatic non-squamous NSCLC that has a RAS G12D mutation.

  Recruiting at 4 sites Phase 3 Revolution Medicines, Inc. · Anchorage, Alaska and 3 other locations · NCT07777822

• XTX501 in people with metastatic NSCLC and advanced solid tumors

  A first-in-human study tests XTX501, a PD-1/masked IL-2 drug, to see if it is safe and tolerable in people with metastatic NSCLC and selected advanced solid tumors.

  Recruiting at 3 sites Phase 1/2 Xilio Development, Inc. · Canton, Ohio and 2 other locations · NCT07688577

• REGN15505 Alone or With Cemiplimab or REGN4336 in Advanced Prostate Cancer and Kidney Cancer

  This trial tests REGN15505 by itself or with cemiplimab or REGN4336 to see if it helps adults with metastatic castration-resistant prostate cancer or clear cell renal cell carcinoma.

  Recruiting at 6 sites Phase 1/2 Regeneron Pharmaceuticals · Goodyear, Arizona and 5 other locations · NCT07594106

• Combining gemcitabine, cisplatin, nab-paclitaxel and cemiplimab to shrink locally advanced biliary tract cancer

  This trial will try whether giving gemcitabine, cisplatin, nab-paclitaxel plus cemiplimab can shrink previously inoperable biliary tract cancers so surgery becomes possible.

  Recruiting Phase 2 Columbia University · New York, New York · NCT07433673

• Amivantamab plus single‑agent chemotherapy for advanced non‑small cell lung cancer with EGFR exon 20 insertion in people unable to receive platinum

  This trial will test whether adding amivantamab to a single chemotherapy drug helps people with metastatic non‑small cell lung cancer that has an EGFR exon 20 insertion who cannot get platinum chemotherapy.

  Recruiting Phase 2 Fondazione Ricerca Traslazionale · Roma, Roma (RM) · NCT07392658

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.